United Therapeutics Q1 revenue falls 2%, misses estimates

United Therapeutics

06/05/2026 11:38

Overview

US rare disease therapy maker's Q1 revenue fell 2% yr/yr, missing analyst expectations

Net income for Q1 declined 15% yr/yr

Company approved $2 bln share repurchase, executed $1.5 bln via accelerated agreements

Outlook

Company aims to return to sequential quarterly revenue growth across commercial portfolio in near term

United Therapeutics plans further development in pulmonary hypertension and fibrosis for ralinepag DPI

Company says positive clinical trial results may support future growth and revenue diversification

Result Drivers

TYVASO PRODUCT MIX - Revenue decline in total Tyvaso driven by lower Nebulized Tyvaso sales, partially offset by growth in Tyvaso DPI; Tyvaso DPI growth was primarily due to higher quantities sold and some price increase

REMODULIN AND ORENITRAM TRENDS - Remodulin sales fell due to lower quantities sold, while Orenitram revenue rose on higher sales volume

COST OF SALES INCREASE - Cost of sales rose mainly due to higher inventory reserve expense, including an estimated loss from a Tyvaso DPI supply agreement

Company press release: ID:nBw3cw5Npa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$781.50 mln
$796.92 mln (11 Analysts)
Q1 EPS
$5.82
Q1 Net Income
$274.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for United Therapeutics Corp is $655.00, about 14.5% above its May 5 closing price of $572.20

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)